Congratulations to Seaport Therapeutics for being named an Endpoints 11 winner as one of biopharma’s most promising startups in 2024!
We are incredibly honored to be named an Endpoints 11 winner – an award that recognizes the most exciting biotechs of 2024 from around the globe. Seaport is built on a proven development strategy and is led by the team – including Daphne Zohar and Dr. Steven Paul – involved in creating and advancing the groundbreaking therapeutic Cobenfy (formerly KarXT). Notably, our CEO Daphne Zohar accepted this award at the Endpoints News gala last night just moments after the FDA announced its approval of Cobenfy for the treatment of schizophrenia in adults. We applaud all those involved in the success of Karuna Therapeutics and the development of Cobenfy. Most importantly, we celebrate this tremendous victory for patients and their families. At Seaport, our development strategy echoes the fundamentals of what this team did with Karuna, and we are committed to delivering the next big breakthroughs in neuropsychiatric drug development with our first and best-in-class medicines for those that are suffering from #depression, #anxiety and other neuropsychiatric disorders. https://lnkd.in/eDDtjy5p